U.S. Markets closed

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018

CRANBURY, N.J., May 15, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2018.

Palatin Technologies, Inc.

Recent Highlights

  • Bremelanotide - Under development for Hypoactive Sexual Desire Disorder ("HSDD"):

"The submission of this NDA represents a significant milestone for the bremelanotide clinical program and our efforts to develop a treatment for HSDD," said Carl Spana, Ph.D., CEO and President of Palatin Technologies.

  • Melanocortin Receptor 1 Agonists ("MC1r") – under development for inflammatory bowel diseases and ocular indications:

Third Quarter Fiscal 2018 Financial Results
Palatin reported a net loss of $(0.7) million, or $(0.00) per basic and diluted share, for the quarter ended March 31, 2018, compared to a net loss of $(3.6) million, or $(0.02) per basic and diluted share, for the same period in 2017.

The difference in financial results between the three months ended March 31, 2018 and 2017 was mainly attributable to the decrease in total operating expenses of $4.3 million that is offset by a decrease of $1.8 million of recognized revenue during the 2018 period pursuant to our license agreement with AMAG.

Revenue
For the quarter ended March 31, 2018, Palatin recognized $9.0 million in license and contract revenue compared to $10.8 million in the same period in 2017. For both periods, 100% of the revenue Palatin recognized was related to our license agreement with AMAG. As of March 31, 2018, and June 30, 2017, there was $0.6 million and $35.1 million, respectively, of current deferred revenue on the consolidated balance sheet related to this transaction.

Operating Expenses
Total operating expenses for the quarter ended March 31, 2018 were $9.5 million compared to $13.8 million for the same period in 2017. The decrease in operating expenses was mainly attributable to professional services rendered in connection with our license agreement with AMAG, which closed in February 2017, and secondarily to the decrease in development expenses of bremelanotide for HSDD as we continue our progress with our bremelanotide program.

Other Income/Expense
Total other income/expense, net was $0.2 million for the quarter ended March 31, 2018 compared to $0.6 million for the same period in 2017. Total other income/expense, net for both periods consisted primarily of interest expense related to Palatin's venture debt.

Income Tax
Palatin licensed bremelanotide to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. ("Fosun") for the People's Republic of China, Taiwan, Hong Kong and Macau, and to Kwangdong Pharmaceutical Co. Ltd. ("Kwangdong") for the Republic of Korea. Pursuant to the license agreements with Fosun and Kwangdong, $500,000 and $82,500, respectively, was withheld in accordance with tax withholding requirements in China and the Republic of Korea, respectively, and will be recorded as an expense during the fiscal year ending June 30, 2018. For the quarter ended March 31, 2018, Palatin recorded an income tax benefit of $18,746 related to those withholding amounts utilizing an estimated effective annual income tax rate applied to the loss for the quarter and the remaining balance of $275,111 was included in prepaid expenses and other current assets at March 31, 2018. Any potential credit to be received by Palatin on its United States tax returns is currently offset by Palatin's valuation allowance. 

Cash Position
Palatin's cash, and cash equivalents were $25.7 million as of March 31, 2018, compared to cash, cash equivalents, accounts receivable and investments of $55.6 million at June 30, 2017. Current liabilities were $13.6 million, net of current deferred revenue of $0.6 million, as of March 31, 2018, compared to $19.9 million, net of deferred revenue of $35.1 million, as of June 30, 2017.

In April 2018, Palatin entered into an equity distribution agreement ("at-the-market program") with Canaccord Genuity LLC, pursuant to which Palatin may, from time to time, sell shares of its common stock at market prices. Palatin has no obligation to sell any shares under this agreement and may, at any time, suspend solicitation and offers under this agreement.

Palatin believes that existing capital resources, together with proceeds from sales of common stock in its at-the-market program (if any), will be sufficient to fund our planned operations through at least June 30, 2019.

Conference Call / Webcast
Palatin will host a conference call and webcast on May 15, 2018 at 11:00 a.m. Eastern Time to discuss the results of operations in greater detail and provide an update on corporate developments. Individuals interested in listening to the conference call live can dial 1-800-263-0877 (domestic) or 1-323-794-2094 (international), conference ID 1551025. The webcast and replay can be accessed by logging on to the "Investor/Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and webcast replay will be available approximately one hour after the completion of the call. To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), passcode 1551025. The webcast and telephone replay will be available through May 22, 2018.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com.  

Forward-looking Statements
Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates and market potential for product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully obtain regulatory approvals, complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

(Financial Statement Data Follows)

 









PALATIN TECHNOLOGIES, INC.

and Subsidiary

Consolidated Statements of Operations

(unaudited)










Three Months Ended March 31,


Nine Months Ended March 31,


2018


2017


2018


2017









REVENUES:








  License and contract revenue

$          8,962,709


$        10,823,748


$        46,516,370


$        10,823,748









OPERATING EXPENSES:








  Research and development

7,068,849


9,062,316


27,277,830


28,422,975

  General and administrative

2,411,302


4,773,696


5,581,066


7,289,342

    Total operating expenses

9,480,151


13,836,012


32,858,896


35,712,317









    (Loss) Income from operations

(517,442)


(3,012,264)


13,657,474


(24,888,569)









OTHER INCOME (EXPENSE):








   Interest income

86,496


6,304


219,578


18,940

   Interest expense

(326,983)


(558,702)


(1,175,023)


(1,777,222)

     Total other expense, net

(240,487)


(552,398)


(955,445)


(1,758,282)









     (Loss) Income before income taxes

(757,929)


(3,564,662)


12,702,029


(26,646,851)

Income tax benefit, net 

18,746


-


192,611


-









NET (LOSS) INCOME

$           (739,183)


$        (3,564,662)


$        12,894,640


$      (26,646,851)









Basic net (loss) income per common share

$                 (0.00)


$                 (0.02)


$                   0.07


$                 (0.15)









Diluted net (loss) income per common share

$                 (0.00)


$                 (0.02)


$                   0.06


$                 (0.15)









Weighted average number of common shares

outstanding used in computing basic net (loss)

income per common share

197,485,758


196,580,519


197,277,286


179,841,133









Weighted average number of common shares

outstanding used in computing diluted net (loss)

income per common share

197,485,758


196,580,519


202,712,963


179,841,133

 

PALATIN TECHNOLOGIES, INC.

and Subsidiary

Consolidated Balance Sheets

(unaudited)






March 31, 2018


June 30, 2017

ASSETS




Current assets:




   Cash and cash equivalents

$               25,736,158


$               40,200,324

   Available-for-sale investments

-


249,837

   Accounts receivable

-


15,116,822

   Prepaid expenses and other current assets

701,456


1,011,221

     Total current assets

26,437,614


56,578,204





Property and equipment, net

165,080


198,153

Other assets

556,915


56,916

     Total assets

$               27,159,609


$               56,833,273





LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)




Current liabilities:




   Accounts payable 

$                    793,642


$                 1,551,367

   Accrued expenses

5,894,877


10,521,098

   Notes payable, net of discount and debt issuance costs

6,921,032


7,824,935

   Capital lease obligations

-


14,324

   Deferred revenue

585,519


35,050,572

     Total current liabilities

14,195,070


54,962,296





Notes payable, net of discount and debt issuance costs

1,328,973


6,281,660

Deferred revenue

500,000


-

Other non-current liabilities

909,179


753,961

     Total liabilities

16,933,222


61,997,917





Stockholders' equity (deficiency):




   Preferred stock of $0.01 par value – authorized 10,000,000 shares:




     Series A Convertible: issued and outstanding 4,030 shares as of

     March 31, 2018 and June 30, 2017

40


40

   Common stock of $0.01 par value – authorized 300,000,000 shares:




     issued and outstanding 195,477,332 shares as of March 31, 2018

     and 160,515,361 shares as of June 30, 2017, respectively

1,954,773


1,605,153

   Additional paid-in capital

352,125,554


349,979,373

   Accumulated other comprehensive loss

-


(590)

   Accumulated deficit 

(343,853,980)


(356,748,620)

     Total stockholders' equity (deficiency)

10,226,387


(5,164,644)

     Total liabilities and stockholders' equity (deficiency)

$               27,159,609


$               56,833,273





 

Cision

View original content with multimedia:http://www.prnewswire.com/news-releases/palatin-technologies-inc-reports-third-quarter-fiscal-year-2018-results-teleconference-and-webcast-to-be-held-on-may-15-2018-300648225.html